reports
- Martial Descoutures
- Emira Sagaama
- Maissa Keskes
- Stephane Houri
AC ACCOR SA
DG VINCI SA
BVI BUREAU VERITAS SA
ADP AEROPORTS DE PARIS SA
RNO RENAULT SA
MTX MTU AERO ENGINES AG
ORA ORANGE SA
SK SEB SA
SW SODEXO SA
ALV ALLIANZ SE
NOKIA NOKIA OYJ
BEI BEIERSDORF AG
ENI ENI S.P.A.
SCHP SCHINDLER HOLDING AG PREF
SAN SANOFI
SAF SAFRAN S.A.
01913 PRADA S.P.A.
BKT BANKINTER SA
ASSA B ASSA ABLOY AB CLASS B
TEC TECHNIPFMC PLC
DHER DELIVERY HERO SE
STM STMICROELECTRONICS NV
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
ULA UNIBAIL-RODAMCO-WESTFIELD SE STAPLED SECS CONS OF 1 SH UNIBAIL RODAMCO + 1 SH WFD UNIB ROD
SIK SIKA AG
HAG HENSOLDT AG
DSY DASSAULT SYSTEMES SA
ATCO A ATLAS COPCO AB
SGSN SGS SA
- Emira Sagaama
- Maissa Keskes
- Stephane Houri
AC ACCOR SA
DG VINCI SA
BVI BUREAU VERITAS SA
ADP AEROPORTS DE PARIS SA
RNO RENAULT SA
MTX MTU AERO ENGINES AG
ORA ORANGE SA
SK SEB SA
SW SODEXO SA
ALV ALLIANZ SE
NOKIA NOKIA OYJ
BEI BEIERSDORF AG
ENI ENI S.P.A.
SCHP SCHINDLER HOLDING AG PREF
SAN SANOFI
SAF SAFRAN S.A.
01913 PRADA S.P.A.
BKT BANKINTER SA
ASSA B ASSA ABLOY AB CLASS B
TEC TECHNIPFMC PLC
DHER DELIVERY HERO SE
STM STMICROELECTRONICS NV
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
ULA UNIBAIL-RODAMCO-WESTFIELD SE STAPLED SECS CONS OF 1 SH UNIBAIL RODAMCO + 1 SH WFD UNIB ROD
SIK SIKA AG
HAG HENSOLDT AG
DSY DASSAULT SYSTEMES SA
ATCO A ATLAS COPCO AB
SGSN SGS SA
- Martial Descoutures
- Ahmed Ben Salem
- Ahmed Ben Salem
- Stephane Foucaud
AUCTUS ON FRIDAY - 24/10/2025
AUCTUS PUBLICATIONS ________________________________________ Condor Energies (CDR CN)C; Target price of C$5.80 per share: Well results derisk the deeper clastic play. The horizontal leg could add 13-20 mmcf/d – Condor’s inaugural well in Uzbekistan has intersected 28.5 meters of net gas pay within the productive carbonate reservoir; which in line with expectations. The company now plans to drill a 1,000-meter horizontal section through this interval, with results anticipated in November. IP rate...
- Alvaro del Pozo
ENI: RDOS. 3T’25 (ANÁLISIS BANCO SABADELL)
Rdos. 3T'25 vs 3T'24: EBIT: 2.073 M euros (-15,1% vs -21,8% BS(e) y -21,0% consenso); BDI: 1.247 M euros (-1,9% vs -18,6% BS(e) y -19,7% consenso). Rdos. 9meses'25 vs 9meses'24: EBIT: 6.562 M euros (-24,2% vs -26,1% BS(e) y -25,8% consenso); BDI: 3.793 M euros (-13,2% vs -18,1% BS(e) y -18,4% consenso).
- Rafael Bonardell
SANOFI: RDOS. 3T’25 (ANÁLISIS BANCO SABADELL)
Rdos. 3T'25 vs 3T'24: Ventas: 12.434 M euros (-7,5% vs -9,7% BS(e) y -9,0% consenso); EBIT: 4.445 M euros (-3,5% vs -10,3% BS(e) y -10,2% consenso). Rdos. 9meses'25 vs 9meses'24: Ventas: 32.323 M euros (-6,7% vs -7,6% BS(e) y -7,3% consenso); EBIT: 9.808 M euros (-4,4% vs -7,5% BS(e) y -7,4% consenso).
- Research Department
INFORME DIARIO 24 OCTUBRE + RDOS. ESPAÑA Y EUROPA 3T’25. IDEAS DESTACA...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: FERROVIAL, INDRA, NEINOR HOMES, VISCOFAN. EUROPA: BNP, ENI, SAFRAN, SANOFI, VINCI Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 3T’25 que se publicarán en España y Europa en los próximos días. A la espera del dato de inflación en EE.UU. Jornada de menos a más en las bolsas europeas, con unos mercados que ...
Press release: Q3: continued sales and earnings progress
Press release: Q3: continued sales and earnings progress Q3: continued sales and earnings progress Paris, October 24, 2025 Q3 sales growth of 7.0% at CER1 and business earnings per share (EPS)2 of €2.91 Pharma launches increased sales by 57.1%, reaching €1.0 billion, driven by ALTUVIIIO and Ayvakit Dupixent sales increased by 26.2% to €4.2 billion, first time above €4 billion in a quarter Vaccines sales decreased by 7.8% to €3.4 billion, from lower influenza sales Research and Development expenses were €1.8 billion, an increase of 4.9% Selling, general and administrative expenses w...
Communiqué de presse : T3 : croissance continue du chiffre d’affaires ...
Communiqué de presse : T3 : croissance continue du chiffre d’affaires et du bénéfice T3 : croissance continue du chiffre d’affaires et du bénéfice Paris, le 24 octobre 2025 Ventes du T3 en progression de 7,0 % à TCC1 et BNPA2 des activités de 2,91 euros Les ventes des nouveaux lancements pharmaceutiques progressent de 57,1 %, atteignant 1,0 milliard d’euros, supportées par ALTUVIIIO et Ayvakit Les ventes de Dupixent progressent de 26,2 %, atteignant 4,2 milliards d’euros, dépassant pour la première fois le seuil trimestriel de 4 milliards d’euros Les ventes de Vaccins diminuent de 7,8 ...
- Emira Sagaama
- Maissa Keskes
- Stephane Houri
AKRBF AKER BP ASA
REL RELX PLC
FP TOTAL SE
HEIA HEINEKEN NV
IPN IPSEN SA
PEO BANK POLSKA KASA OPIEKI SA
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
CA CARREFOUR SA
BVI BUREAU VERITAS SA
KNEBV KONE OYJ CLASS B
RNO RENAULT SA
LI KLEPIERRE SA
KPN ROYAL KPN NV
COV COVIVIO SA
ROG ROCHE HOLDING LTD
MTX MTU AERO ENGINES AG
ORA ORANGE SA
HO THALES SA
RMS HERMES INTERNATIONAL SCA
LONN LONZA GROUP AG
SW SODEXO SA
EN BOUYGUES SA
RXL REXEL SA
LSEG LONDON STOCK EXCHANGE GROUP PLC
NOKIA NOKIA OYJ
BEI BEIERSDORF AG
PKO PKO BANK POLSKI S.A.
KER KERING SA
REE RED ELECTRICA CORP. SA
ENI ENI S.P.A.
SPL SANTANDER BANK POLSKA SA
REP REPSOL SA
MIL BANK MILLENNIUM SA
ARCAD ARCADIS NV
UCG UNICREDIT S.P.A.
ALR ALIOR BANK SA
SAP SAP SE
BP. BP P.L.C.
STM STMICROELECTRONICS NV
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
IHG INTERCONTINENTAL HOTELS GROUP PLC
MRNA MODERNA INC.
DSY DASSAULT SYSTEMES SA
SHEL SHELL PLC
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
SGSN SGS SA
- Emira Sagaama
- Maissa Keskes
- Stephane Houri
AKRBF AKER BP ASA
REL RELX PLC
FP TOTAL SE
HEIA HEINEKEN NV
IPN IPSEN SA
PEO BANK POLSKA KASA OPIEKI SA
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
CA CARREFOUR SA
BVI BUREAU VERITAS SA
KNEBV KONE OYJ CLASS B
RNO RENAULT SA
LI KLEPIERRE SA
KPN ROYAL KPN NV
COV COVIVIO SA
ROG ROCHE HOLDING LTD
MTX MTU AERO ENGINES AG
ORA ORANGE SA
HO THALES SA
RMS HERMES INTERNATIONAL SCA
LONN LONZA GROUP AG
SW SODEXO SA
EN BOUYGUES SA
RXL REXEL SA
NOKIA NOKIA OYJ
BEI BEIERSDORF AG
PKO PKO BANK POLSKI S.A.
KER KERING SA
REE RED ELECTRICA CORP. SA
ENI ENI S.P.A.
SPL SANTANDER BANK POLSKA SA
REP REPSOL SA
MIL BANK MILLENNIUM SA
ARCAD ARCADIS NV
UCG UNICREDIT S.P.A.
ALR ALIOR BANK SA
SAP SAP SE
BP. BP P.L.C.
STM STMICROELECTRONICS NV
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
IHG INTERCONTINENTAL HOTELS GROUP PLC
MRNA MODERNA INC.
DSY DASSAULT SYSTEMES SA
SHEL SHELL PLC
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
SGSN SGS SA
- Emira Sagaama
- Emmanuel Matot
IPS IPSOS
FP TOTAL SE
PEO BANK POLSKA KASA OPIEKI SA
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
ORA ORANGE SA
SSAB A SSAB AB CLASS A
EN BOUYGUES SA
CEN GROUPE CRIT SA
IDL ID LOGISTICS GROUP
SDG SYNERGIE SA
ITP INTERPARFUMS
BLC BASTIDE LE CONFORT MEDICAL SA
PKO PKO BANK POLSKI S.A.
LPE LAURENT-PERRIER SA
GOE GROUPE GORGE SA
FNAC FNAC DARTY SA
ENI ENI S.P.A.
NEX NEXANS SA
ICAD ICADE SA
SPL SANTANDER BANK POLSKA SA
REP REPSOL SA
MIL BANK MILLENNIUM SA
VRNL VERNEUIL PARTICIPATIONS
ERG ERG S.P.A.
CTAC CTAC N.V.
TPS ORANGE POLSKA S.A.
AOF ATOSS SOFTWARE AG
RIEN RIETER HOLDING AG
SESL SES-IMAGOTAG SA
CIE CIE AUTOMOTIVE S.A.
AALB AALBERTS N.V.
CON CONZZETA AG
NVG NAVIGATOR COMPANY SA
INSD VERIMATRIX SA
ALR ALIOR BANK SA
VLTSA VOLTALIA
ECONT ECONOCOM GROUP SE CLASS D
BP. BP P.L.C.
GALE GALENICA AG
VRLA VERALLIA SAS
AZE AZELIS GROUP NV
SHEL SHELL PLC
SPM SAIPEM S.P.A.
4X0 STEYR MOTORS AG
- Ahmed Ben Salem
- Thijs Berkelder
- Ahmed Ben Salem
- Thijs Berkelder
Press Release: Sanofi’s efdoralprin alfa met all primary and key secon...
Press Release: Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study Efdoralprin alfa demonstrated superiority in a head-to-head study versus a standard of care plasma-derived therapy Results reinforce the potential of efdoralprin alfa to be the first restorative recombinant therapy that normalizes and maintains functional AAT levels Phase 2 data support both three-week and four-week dosing ...
Communiqué de presse : L’efdoralprine alfa de Sanofi a atteint tous le...
Communiqué de presse : L’efdoralprine alfa de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase II sur l’emphysème par déficit en alpha-1-antitrypsine L’efdoralprine alfa de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase II sur l’emphysème par déficit en alpha-1-antitrypsine L’efdoralprine alfa a démontré sa supériorité dans une une étude comparative directe par rapport à un traitement standard dérivé du plasmaLes résultats renforcent l’effet potentiel de l’efdoralprine alfa de consti...
Press Release: Sanofi’s Tzield accepted for expedited review in the US...
Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program If approved, Tzield would be the first disease-modifying therapy to delay the progression of stage 3 T1D in adults and pediatric patients eight years of age and older recently diagnosed with stage 3 T1DTzield is also being reviewed under the accelerated approval program Paris,...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.